Abstract #2376
Clinically uncertain parkinsonism shows nigral depigmentation in the presence and absence of dopaminergic deficit: a multimodal imaging study
YUE XING1,2,3, Saadnah Naidu1,2,3, Marta Gennaro4,5, Andreas Antonios-Roussakis6, Nicholas P. Lao-Kaim4, Halim Abdul-Sapuan1,2,3, Jonathan Evans7, Gillian Sare7, Antonio Martin-Bastida4,8, Schwarz T. Stefan1,2,9, Paola Piccini4,6, and Dorothee P Auer1,2,3
1Mental Health and Clinical Neuroscience Unit, University of Nottingham, Nottingham, United Kingdom, 2Sir Peter Mansfield Imaging Centre, University of Nottingham, Nottingham, United Kingdom, 3NIHR Nottingham Biomedical Research Centre, University of Nottingham, Nottingham, United Kingdom, 4Division of Neurology, Imperial College London, London, United Kingdom, 5Nuclear Medicine department, Royal Brompton & Harefield hospitals, London, United Kingdom, 6NHLI Department, Imperial College London, London, United Kingdom, 7Nottingham University Hospitals, Nottingham, United Kingdom, 8Department of Neurology and Neurosciences, Clínica Universidad de Navarra, Pamplona-Madrid, Spain, 9Department of Radiology, Cardiff and Vale University Health Board, Cardiff, United Kingdom
Synopsis
Brain dopamine transporter (DAT) imaging with 123I-FP-CIT SPECT has been used for detecting striatal deficits in clinically uncertain parkinsonism (CUP). Neuromelanin(NM)-MRI assesses nigral depigmentation with high accuracy in confirmed PD; but its diagnostic value in CUP is unclear. Here, we compare nigral NM in CUP with (DAT+) or without (DAT-) striatal dopaminergic deficits, to established PD and healthy controls. CUP with DAT+ had more nigral NM deficits (vs. controls and DAT-CUP) but were less pronounced than in established PD. Interestingly, DAT- cases showed ventrolateral nigral deficits. Our results suggest that nigral depigmentation possibly starts before striatal dopaminergic decline.
This abstract and the presentation materials are available to members only;
a login is required.
Join Here
